Completed PHASE2 INTERVENTIONAL NCT00024544

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma

Sponsor: Facet Biotech

Conditions Asthma

Interventions anti-IL-4 monoclonal antibody (pascolizumab)

Updated 7 times since 2017 Last updated: Mar 6, 2012 Started: Aug 31, 2001 Primary completion: Feb 28, 2003 Completion: Feb 28, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Facet Biotech and has accumulated 7 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Facet Biotech

Data source: Facet Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Denver, United States , Easton, United States , Houston, United States , Lake Oswego, United States , Los Angeles, United States , Madison, United States , Minneapolis, United States , Mission Viejo, United States , Normal, United States and 8 more locations